MTCR Metacrine, Inc.

Metacrine is a clinical-stage biopharmaceutical company building a potentially best-in-class pipeline of drugs to treat liver and gastrointestinal (GI) diseases. The company’s most advanced programs, MET409 and MET642, target the farnesoid X receptor (FXR), which is central to modulating liver and GI diseases. Both MET409 and MET642 are currently being investigated in clinical trials as a potential new treatment for non-alcoholic steatohepatitis (NASH).

$8.60
As of 03/05/2021     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Micro cap
Health Care
Biotechnology
USA
USA
09/16/2020
25,956,300
41,568
$223,224,180
0.00%
SEC Edgar Online
10-Q
10-K
59101E103
US59101E1038
BKY4502

Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
0.00
2.27
0.00
-25.38%
0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy